Idorsia discovers, develops, and commercialises small-molecule medicines that transform treatment options for patients with unmet medical needs. Founded in 2017 from the Actelion demerger, the company produces a diversified pipeline across CNS disorders, cardiovascular conditions, immunological diseases, and rare conditions. Its flagship product QUVIVIQ (daridorexant) offers a different approach to treating insomnia. Headquartered near Basel, Switzerland, Idorsia employs around 550 professionals covering laboratory research through commercial launch. The company balances in-house development with strategic partnerships, operating with financial discipline whilst advancing differentiated assets that can change how diseases are treated.
552
Team Members
2017
Founded
Pharma
Sector
On-Site
Work Environment
A world where innovative small-molecule medicines transform treatment paradigms, offering patients genuine therapeutic alternatives that address the root causes of disease rather than merely managing symptoms.
At Idorsia, our mission is to discover, develop and commercialize innovative medicines to help more patients.